ORPHA:141000
Orofaciodigital syndrome type 11
Also known as: OFD11 · Oral-facial-digital syndrome type 11 · Oral-facial-digital syndrome, Gabrielli type · Orofaciodigital syndrome, Gabrielli type
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
15
24.9th percentile
Trials
0
Interventional, condition-specific
Researchers
141
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare, sporadic, orofaciodigital syndrome characterized by severe , postaxial polydactyly, vertebral fusion, deafness and heart defects. Characteristic facial features include blepharophimosis, bulbous nasal tip, broad nasal bridge, downslanting palpebral fissures and low-set ears.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013035
- MeSH:C557821
- OMIM:612913
- UMLS:C2752048
Additional Mondo synonyms (5)
oral-facial-digital syndrome type 11 · oral-facial-digital syndrome, Gabrielli type · orofaciodigital syndrome XI · orofaciodigital syndrome type XI · orofaciodigital syndrome, Gabrielli type
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
15 matched papers (8 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
15
15 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
15 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
8 in the last 10 years · high confidence · 24.9th percentile (publications denominator)
Phrase hits: 15 · MeSH hits: 0
Who's working on it?
141
Distinct author names in 15 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Franco B2 papers · 2016
Telethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, Pozzuoli, 80078 Naples, Italy ; Medical Genetics, Department of Medical Translational Sciences, University of Naples Federico II, Naples, Italy.
Papers in Europe PMC - 02Abouelasrar Salama S1 paper · 2022
Laboratory of Molecular Immunology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, University of Leuven, 3000, Leuven, Belgium.
Papers in Europe PMC - 03Abraham Versloot RC1 paper · 2023
Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG Groningen, Netherlands.
Papers in Europe PMC - 04Aftimos S1 paper · 2010Papers in Europe PMC
- 05Alders M1 paper · 2017
Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands.
Papers in Europe PMC - 06Aleck KA1 paper · 2010Papers in Europe PMC
- 07Amin S1 paper · 2009Papers in Europe PMC
- 08Amor D1 paper · 2010Papers in Europe PMC
- 09An Y1 paper · 2025
Dept. of Plastic Surgery, Peking University Third Hospital, Beijing 100191, China.
Papers in Europe PMC - 10Anderson KC1 paper · 2009Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category orofaciodigital syndrome also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: orofaciodigital syndrome
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Orofaciodigital syndrome type 11" OR "OFD11" OR "Oral-facial-digital syndrome type 11" OR "Oral-facial-digital syndrome, Gabrielli type" OR "Orofaciodigital syndrome, Gabrielli type" OR "orofaciodigital syndrome XI" OR "orofaciodigital syndrome type XI"
MeSH descriptor terms unioned into the query: Orofaciodigital syndrome 11
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Orofaciodigital syndrome type 11" OR "OFD11" OR "Oral-facial-digital syndrome type 11" OR "Oral-facial-digital syndrome, Gabrielli type" OR "Orofaciodigital syndrome, Gabrielli type" OR "orofaciodigital syndrome XI" OR "orofaciodigital syndrome type XI" OR "Orofaciodigital syndrome 11"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"orofaciodigital syndrome"
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T07:49:07.446Z